Ultragenyx Pharmaceutical Inc (RARE)
45.10
+1.42
(+3.25%)
USD |
NASDAQ |
Apr 23, 16:00
45.13
+0.03
(+0.07%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Free Cash Flow: -521.57M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -521.57M |
| September 30, 2023 | -553.38M |
| June 30, 2023 | -553.20M |
| March 31, 2023 | -528.78M |
| December 31, 2022 | -526.59M |
| September 30, 2022 | -479.67M |
| June 30, 2022 | -438.49M |
| March 31, 2022 | -415.73M |
| December 31, 2021 | -411.79M |
| September 30, 2021 | -425.79M |
| June 30, 2021 | -411.33M |
| March 31, 2021 | -242.64M |
| December 31, 2020 | -176.12M |
| September 30, 2020 | -175.27M |
| June 30, 2020 | -203.06M |
| March 31, 2020 | -380.63M |
| December 31, 2019 | -370.22M |
| September 30, 2019 | -343.72M |
| June 30, 2019 | -320.37M |
| March 31, 2019 | -303.52M |
| December 31, 2018 | -294.64M |
| Date | Value |
|---|---|
| September 30, 2018 | -320.32M |
| June 30, 2018 | -313.16M |
| March 31, 2018 | -284.90M |
| December 31, 2017 | -256.64M |
| September 30, 2017 | -222.26M |
| June 30, 2017 | -190.98M |
| March 31, 2017 | -186.48M |
| December 31, 2016 | -171.16M |
| September 30, 2016 | -165.18M |
| June 30, 2016 | -166.02M |
| March 31, 2016 | -139.19M |
| December 31, 2015 | -110.93M |
| September 30, 2015 | -81.47M |
| June 30, 2015 | -60.36M |
| March 31, 2015 | -53.71M |
| December 31, 2014 | -46.78M |
| September 30, 2014 | -43.78M |
| June 30, 2014 | -39.26M |
| March 31, 2014 | -36.33M |
| December 31, 2013 | -31.61M |
Free Cash Flow Range, Past 5 Years
-553.38M
Minimum
Sep 2023
-175.27M
Maximum
Sep 2020
-393.60M
Average
-411.79M
Median
Dec 2021
Free Cash Flow Benchmarks
| Corcept Therapeutics Inc | 126.90M |
| Madrigal Pharmaceuticals Inc | -325.71M |
| Sarepta Therapeutics Inc | -588.34M |
| FibroGen Inc | -317.54M |
| Rocket Pharmaceuticals Inc | -211.39M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -83.90M |
| Cash from Investing (Quarterly) | -107.02M |
| Cash from Financing (Quarterly) | 330.61M |
| Free Cash Flow Per Share (Quarterly) | -1.053 |
| Free Cash Flow to Equity (Quarterly) | -85.50M |
| Free Cash Flow to Firm (Quarterly) | -76.98M |
| Free Cash Flow Yield | -15.73% |